Dallas, Texas 07/03/2013 (Financialstrend) – Shares of Acura Pharmaceuticals, Inc (NASDAQ:ACUR) closed at $2.04 on Tuesday, recording a loss of 8.11 percent. The share price ranged between $1.96 and $2.26 during the day, with a 52-week high of $4.50 and a 52-week low of $1.06 per share.
Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) recorded very high trading volumes of 1.20 million shares on Tuesday, whereas the average volume stands at 573,624 shares per day. Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) currently has 46.38 million shares outstanding in the market with a market cap of $94.61 million and an institutional ownership of 77 percent of the total share capital.
Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) is a specialty pharmaceutical company involved in the commercialization, research and development of products focused on issues of medication abuse and misuse.
Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) has announced that Pfizer will expand the Oxecta commercialization. Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) is currently up 144.34 percent higher from its recent 52-week low, eligible for the inclusion of the stock in the Active Stock Watch List NASDAQ’s Growing Stock Report. Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) has licensed its Pfizer’s Aversion technology in Canada, the U.S. and Mexico for use in an immediate-release oxycodone called Oxecta with a tamper resistant design that inhibits recreational use of the drug. The company receives tiered royalties on net sales of Oxecta ranging between 5 and 25 percent. Bob Jones, the president and chief executive officer of Acura, announced that they are pleased Pfizer is advancing the commercialization plan for Oxecta. Pfizer has terminated its license to three development-stage products last year due to the usage of Acura’s tamper-resistant technology, which pulled down the shares of Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) to lower levels.
